Skip to content

Actuate Therapeutics, Inc.: 10-Q filed 2025-11-13

What Actuate Therapeutics, Inc. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 31 published measures, 95 facts as tagged in accession 0001683168-25-008323.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-13
Fiscal period
fiscal Q3 2025
Accession
0001683168-25-008323 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Actuate Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3017,713,934USD
At 2024-12-319,318,448USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-306,777,653USD
At 2024-12-319,214,262USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-3010,936,281USD
At 2025-06-30-2,653,704USD
At 2025-03-31-5,087,737USD
At 2024-12-31104,186USD
At 2024-09-305,358,688USD
At 2024-06-30-114,256,566USD
At 2024-03-31-107,774,366USD
At 2023-12-31-99,626,513USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3016,924,763USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-5,407,470USD92
2025-01-01 to 2025-09-30-17,673,899USD273
2025-04-01 to 2025-06-30-5,949,405USD91
2025-01-01 to 2025-03-31-6,317,024USD90
2024-07-01 to 2024-09-30-5,970,961USD92
2024-01-01 to 2024-09-30-20,839,239USD274
2024-04-01 to 2024-06-30-6,572,219USD91
2024-01-01 to 2024-03-31-8,296,059USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-15,470,210USD273
2024-01-01 to 2024-09-30-17,070,233USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-3023,753,351USD273
2024-01-01 to 2024-09-3027,635,023USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-150,053,748USD
At 2024-12-31-132,379,849USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3021,394,965shares92
2025-01-01 to 2025-09-3020,186,706shares273
2024-07-01 to 2024-09-3010,772,640shares92
2024-01-01 to 2024-09-304,647,199shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3021,394,965shares92
2025-01-01 to 2025-09-3020,186,706shares273
2024-07-01 to 2024-09-3010,772,640shares92
2024-01-01 to 2024-09-304,647,199shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.25USD/shares92
2025-01-01 to 2025-09-30-0.88USD/shares273
2024-07-01 to 2024-09-30-0.55USD/shares92
2024-01-01 to 2024-09-30-4.48USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.25USD/shares92
2025-01-01 to 2025-09-30-0.88USD/shares273
2024-07-01 to 2024-09-30-0.55USD/shares92
2024-01-01 to 2024-09-30-4.48USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-304,504,986USD273
2024-01-01 to 2024-09-30804,206USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-5,472,378USD92
2025-01-01 to 2025-09-30-17,806,839USD273
2024-07-01 to 2024-09-30-5,392,903USD92
2024-01-01 to 2024-09-30-18,601,606USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3017,444,000USD
At 2024-12-319,207,900USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-306,372,662USD
At 2024-12-318,802,503USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-301,245,375USD
At 2024-12-311,921,189USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,472,378USD92
2025-01-01 to 2025-09-3017,806,839USD273
2024-07-01 to 2024-09-305,392,903USD92
2024-01-01 to 2024-09-3018,601,606USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,177,922USD92
2025-01-01 to 2025-09-308,163,046USD273
2024-07-01 to 2024-09-303,757,102USD92
2024-01-01 to 2024-09-3014,990,337USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3023,243,328shares
At 2024-12-3119,531,636shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3016,924,763USD
At 2024-12-318,641,622USD
At 2024-09-3013,523,449USD
At 2023-12-312,958,659USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-30160,990,006USD
At 2024-12-31132,484,015USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-30269,934USD
At 2024-12-31110,548USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30519,237USD
At 2024-12-31566,278USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,294,456USD92
2025-01-01 to 2025-09-309,643,793USD273
2024-07-01 to 2024-09-301,635,801USD92
2024-01-01 to 2024-09-303,611,269USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,063USD92
2025-01-01 to 2025-09-3015,188USD273
2024-07-01 to 2024-09-303,489USD92
2024-01-01 to 2024-09-3013,641USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-3064,908USD92
2025-01-01 to 2025-09-30132,940USD273
2024-07-01 to 2024-09-30-578,058USD92
2024-01-01 to 2024-09-30-2,237,633USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-3070,957USD273
2024-01-01 to 2024-09-3071,033USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-01-01 to 2025-09-30800USD273
2024-01-01 to 2024-09-30800USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-303,826,336USD273
2024-01-01 to 2024-09-300USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-698,091USD273
2024-01-01 to 2024-09-30-1,197,747USD274

Inspect the source

Entity
Actuate Therapeutics, Inc. / CIK 0001652935
Captured
2026-09-21T17:22:53.999Z
SEC response SHA-256
7d9d1e27bcddbc6cd73d08a9f2cb4fecbb70bc549dfbdb27bf0d7e913e24dd0e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001652935.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))